Clinical Trial Update: A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing intravenous mirvetuximab soravtansine in platinum-resistant, FR-alpha–high expressing advanced high-grade epithelial ovarian ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Mirvetuximab soravtansine (mirvetuximab soravtansine)

Snippet

Sponsor: AbbVie | Conditions: Advanced High-Grade Epithelial Ovarian, Primary Peritoneal | Phase 2 | Status: RECRUITING